jRCT2031220507进行中（未招募）不适用
A Phase 1 Clinical Study to Evaluate the Bioavailability of Pembrolizumab via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants with Advanced Solid Tumors
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- MSD K.K.
- 入组人数
- 96
- 主要终点
- PK exposure measures in Cycle 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Has histologically- or cytologically-confirmed diagnosis of Non Small Cell Lung Cancer (NSCLC) (Arm 3).
- •Can provide archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
- •Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.
- •Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group Performance Scale.
- •Demonstrates adequate organ function.
排除标准
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.
- •Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before the first dose of study intervention, or has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or better from any adverse events (AEs) that were due to cancer therapeutics administered more than 4 weeks earlier (this includes participants with previous immunomodulatory therapy with residual immune-related AEs).
- •Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
- •Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Has severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients.
- •Has an active infection requiring therapy.
- •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years.
- •Has known hepatitis B or C infections or known to be positive for hepatitis B surface antigen (HBsAg)/hepatitis B virus deoxyribonucleic acid (DNA) or hepatitis C antibody or ribonucleic acid (RNA)
- •Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- •Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study.
- •Has not fully recovered from any effects of major surgery without significant detectable infection.
- •Has symptomatic ascites or pleural effusion.
- •Has preexisting peripheral neuropathy that is >Grade 2 by latest NCI CTCAE version
- •Has a known sensitivity to recombinant hyaluronidase or other form of hyaluronidase.
- •Has a history of severe hypersensitivity reaction (eg, generalized rash/erythema, hypotension, bronchospasm, angioedema, or anaphylaxis) to pemetrexed, cisplatin, axitinib, carboplatin, paclitaxel, or nab-paclitaxel.
- •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
结局指标
主要结局
PK exposure measures in Cycle 1
时间窗: Cycle 1
including trough concentration (Ctrough), maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax), and area under the curve (AUC)
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
3 期
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan ExtensionMetastatic Non-small Cell Lung CancerNCT06212752Merck Sharp & Dohme LLC39
进行中（未招募）
3 期
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Metastatic Non-small Cell Lung CancerNCT05722015Merck Sharp & Dohme LLC377
进行中（未招募）
1 期
Ph 3 Trial of MK-3475 (Pembrolizumab) vs Standard Treatment in Recurrent/Metastatic Head and Neck CancerEUCTR2014-001749-26-PTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.495
进行中（未招募）
1 期
Ph 3 Trial of MK-3475 (Pembrolizumab) vs Standard Treatment in Recurrent/Metastatic Head and Neck CancerRecurrent or Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 19.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001749-26-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.466
进行中（未招募）
1 期
Ph 3 Trial of MK-3475 (Pembrolizumab) vs Standard Treatment in Recurrent/Metastatic Head and Neck CancerEUCTR2014-001749-26-NLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.466